The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2018 | The importance of MRD status in MM
There are many questions surrounding minimal residual disease (MRD) detection and its role in decision making; for example, whether drug administration should be continued in a multiple myeloma (MM) patient who is MRD negative, or whether to change the treatment given if a patient is MRD positive. Here, Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, speaking from the 23rd congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden, discusses the importance of MRD negative complete remission, and how clinical trials such as POLLUX (NCT02076009) and CASTOR (NCT02136134) have established that MRD negative patients have a greater progression-free survival.
